FDA to discuss easing restrictions on peptides despite safety concerns
Summary
The FDA will soon meet to discuss whether to loosen rules on certain research peptides, drugs that have growing popularity but limited proof they are safe or work well. These drugs are currently blocked from being made by U.S. compounding pharmacies, but easing restrictions would allow wider access despite ongoing safety concerns.Key Facts
- The FDA's advisory committee will meet on July 23-24 to discuss seven peptides, including BPC-157 and Semax.
- If restrictions are eased, U.S. compounding pharmacies could legally produce these peptides for prescriptions.
- Peptides are short chains of amino acids, including known drugs like insulin and newer ones for weight loss.
- Some research peptides are sold online as wellness aids but lack strong safety or effectiveness evidence.
- Many peptides come from overseas compounding pharmacies and are popular on social media.
- Experts warn that these peptides have little human testing and possible health risks.
- The FDA typically follows advisory committee advice but does not have to.
- Even if allowed, these peptides will not be officially approved by the FDA, which requires years of trials.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.